eli lilly glp 1 market share Shows Why the GLP-1 Trade Is Still About Volume, Not Pricing GLP-1 Receptor Agonist Market Size

In 2005, the first GLP-1 receptor agonist, exenatide (marketed as Byetta), was approved by the US Food and Drug Administration and subsequently received European authorisation through the European Medicines Agency (EMA)

Liraglutide in the treatment of type 2 diabetes: Recommendations for better patients selection from a multidisciplinary approach

An accumulating body of studies is showing positive potential for using GLP-1s for substance use, said Christian Hendershot, director of clinical research at the USC Institute for Addiction Science, Los Angeles

ADM prescribing in September 2025 increased slightly compared to June 2025 (+5.2%)

There are many potential modalities in which GLP-1 can serve a role in protecting against the progression of AD

The controversy around Ozempic While Ozempic has made waves in the film and fashion industry for its ability to aid in weight loss, its increasing use among celebrities and influencers has raised heavy concerns